A 45-year-old Chinese-Canadian woman presented with chemosis of several years' duration. As a teenager the patient had noticed corneal arcus and thickening of her Achilles tendons. At age 20 she was found to have a fasting total cholesterol level of 18.0 (normal < 5.2) mmol/L and a low-density lipoprotein (LDL) cholesterol level of 15.4 (normal < 3.4) mmol/L. On the basis of these findings and a family history of hypercholesterolemia in both parents and premature coronary artery disease in her father, homozygous familial hypercholesterolemia (FH) was diagnosed. The initial treatment was with bile acidbinding resins, followed by the addition of hydroxymethylglutaryl coenzyme A reductase inhibitors, or statins, when she was 29. She has been intolerant of fibrates and niacin, both of which caused rashes. At age 30, angina pectoris necessitated coronary artery bypass grafting, and she has since remained free of cardiovascular symptoms. At age 40, carotid ultrasound imaging, conducted after carotid bruits were detected, revealed more than 95% and 50%-79% stenoses of the left and right carotid arteries respectively. She began taking 325 mg of ASA daily and has remained free of neurologic symptoms. Her total cholesterol level and LDL cholesterol level fell to 10.1 and 8.2 mmol/L respectively after she began taking 80 mg of atorvastatin and 4 g of colestipol daily, and her Achilles tendon xanthomas also shrank over time. Her lipoprotein (a) level was elevated at 0.44 (normal < 0.3) g/L. Her sitosterol level was 2.4 (normal ≤ 5.0) µg/mL, and her homocysteine level was 8.0 (normal < 12.1) µmol/L); her ApoE genotype (ε3/ε3) was also normal. The patient's high-density lipoprotein cholesterol level was 0.8 (normal > 0.9) mmol/L on no lipid therapy and has ranged between 0.6 and 1.1 mmol/L with atorvastatin and colestipol therapy; her triglyceride level was 2.7 (normal < 2.3) mmol/L at baseline and has ranged from 1.4 to 3.6 mmol/L with therapy.A genomic DNA sequence analysis showed that she was homozygous for proline-to-leucine substitution at residue 644 of the LDL receptor known as FH-Zambia 1 or FHGujerat, 2 which has not been reported in Canada. 3 This mutation is associated with slowed maturation and attenuated cell-surface expression of LDL receptors 4 but does not abolish receptor function. Partial LDL receptor function appears to explain the patient's responsiveness to therapy, which was better than expected for most patients with homozygous FH. The addition of 10 mg daily of ezetimibe to the atorvastatin and colestipol therapy lowered the patient's LDL cholesterol level to 6.9 mmol/L. When colestipol was discontinued, this level decreased further to 5.9 mmol/L, which suggests an enhanced response to combination statin-ezetimibe therapy in the absence of bile acid-binding resin. Fig. 1 shows the sites of action of medications taken by the patient. We are considering LDL apheresis to further decrease LDL levels.Ophthalmologic examination revealed bilateral chemosis and conjunctival redness with no ocular hypertension ...